Web Reporter: Abu Dhabi
Phase III clinical trials of Russian adenovirus-based vaccine will commence in the UAE, in line with trials taking place in Russia and elsewhere globally.
The trails will be conducted by the Department of Health- Abu Dhabi under the supervision of the UAE Ministry of Health and Prevention, with medical protocols handled by the Abu Dhabi Health Services Company, SEHA.
The adenovirus-based vaccine is developed by the Gamaleya National Research Institute of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation.
The Russian Direct Investment Fund (RDIF) and Aurugulf Health Investment are partnering on these clinical trials, which are amongst those taking place with volunteers in Russia and elsewhere globally.
